Related references
Note: Only part of the references are listed.Targeting Abnormal DNA Repair in Therapy-Resistant Breast Cancers
Lisa A. Tobin et al.
MOLECULAR CANCER RESEARCH (2012)
Practical Advice for Determining the Role of BCR-ABL Mutations in Guiding Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia
Elias Jabbour et al.
CANCER (2011)
Treatment of chronic myeloid leukemia when imatinib fails
Ruediger Hehlmann et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
Functional Interplay of the Mre11 Nuclease and Ku in the Response to Replication-Associated DNA Damage
Steven S. Foster et al.
MOLECULAR AND CELLULAR BIOLOGY (2011)
Crucial role for DNA ligase III in mitochondria but not in Xrcc1-dependent repair
Deniz Simsek et al.
NATURE (2011)
DNA ligase III is critical for mtDNA integrity but not Xrcc1-mediated nuclear DNA repair
Yankun Gao et al.
NATURE (2011)
CtIP promotes microhomology-mediated alternative end joining during class-switch recombination
Mieun Lee-Theilen et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
An essential role for CtIP in chromosomal translocation formation through an alternative end-joining pathway
Yu Zhang et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy
Jinshui Fan et al.
BLOOD (2010)
Ku Regulates the Non-Homologous End Joining Pathway Choice of DNA Double-Strand Break Repair in Human Somatic Cells
Farjana Fattah et al.
PLOS GENETICS (2010)
Effect of double-strand break DNA sequence on the PARP-1 NHEJ pathway
Marc Audebert et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Up-regulation of WRN and DNA ligase IIIα in chronic myeloid leukernia:: consequences for the repair of DNA double-strand breaks
Annahita Sallmyr et al.
BLOOD (2008)
Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair
Xi Chen et al.
CANCER RESEARCH (2008)
Targeted therapy for cancer using PARP inhibitors
Christopher J. Lord et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Identification and validation of human DNA ligase inhibitors using computer-aided drug design
Shijun Zhong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Reciprocal binding of PARP-1 and histone H1 at promoters specifies transcriptional outcomes
Raga Krishnakumar et al.
SCIENCE (2008)
Array CGH analysis of copy number variation identifies 1284 new genes variant in healthy white males: implications for association studies of complex diseases
Adam J. de Smith et al.
HUMAN MOLECULAR GENETICS (2007)
Human CtIP promotes DNA end resection
Alessandro A. Sartori et al.
NATURE (2007)
Cernunnos/XLF promotes the ligation of mismatched and noncohesive DNA ends
Chun J. Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways
Minli Wang et al.
NUCLEIC ACIDS RESEARCH (2006)
Involvement of polynucleotide kinase in a poly(ADP-ribose) polymerase-1-dependent DNA, double-strand breaks rejoining pathway
M Audebert et al.
JOURNAL OF MOLECULAR BIOLOGY (2006)
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia
S Soverini et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
DNA ligase III as a candidate component of backup pathways of nonhomologous end joining
HC Wang et al.
CANCER RESEARCH (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining
M Audebert et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
A biochemically defined system for mammalian nonhomologous DNA end joining
YM Ma et al.
MOLECULAR CELL (2004)
BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks
MO Nowicki et al.
BLOOD (2004)
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
S Branford et al.
BLOOD (2003)
Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR
K Ohmine et al.
STEM CELLS (2003)
BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability
T Skorski
ONCOGENE (2002)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G2/M phase, and protection from apoptosis
A Slupianek et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
S Branford et al.
BLOOD (2002)
Mutation in the glucose-6-phosphate dehydrogenase gene leads to inactivation of Ku DNA end binding during oxidative stress
IS Ayene et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571:: a prospective study
N von Bubnoff et al.
LANCET (2002)
Does the BCR/ABL-mediated increase in the efficacy of DNA repair play a role in the drug resistance of cancer cells?
I Majsterek et al.
CELL BIOLOGY INTERNATIONAL (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells
M Sattler et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
